Stason, Amerigen in High Containment Manufacturing Pact

Amerigen Pharmaceuticals and Stason Pharmaceuticals have entered into a collaboration agreement regarding the development of generic oral oncology products. Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the U.S. and other territories. Stason received an undisclosed upfront fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

“This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio,” said Jonathan Embleton, chief business officer for Amerigen. “We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration.”

“We have been working hard to leverage our high containment development and manufacturing capabilities,” said Jim Fang, chief operating officer for Stason. “This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal.”